Aisens Affiliate PrecisionBio Passes Preliminary Review for KOSDAQ Listing

[Asia Economy Reporter Minji Lee] Global biosensor specialist i-SENS announced on the 27th that Precision Bio, an in vitro diagnostics (IVD) company in which it holds shares, has passed the preliminary review for KOSDAQ listing by the Korea Exchange.

Precision Bio began the KOSDAQ listing process in earnest after passing the technology evaluation in May. According to the company, it plans to submit a securities registration statement and initiate the public offering process with the goal of listing within the year. The lead underwriter is Korea Investment & Securities.

In September, Precision Bio obtained European certification (CE) for its novel coronavirus disease (COVID-19) diagnostic product (Exdia COVID-19 Ag) based on its proprietary high-sensitivity fluorescence testing platform called Exdia TRF, and launched the product in European countries. Due to the recent resurgence of COVID-19, demand for diagnostic products has surged explosively, and gradual sales growth is expected.

i-SENS is the largest shareholder of Precision Bio, holding a 34% stake as of the half-year mark. i-SENS entered the immunodiagnostics sector within the in vitro diagnostics field through equity investment in Precision Bio and its own technology investments.

An i-SENS official stated, "Even after the KOSDAQ listing of our affiliate Precision Bio, we will continue to pursue synergies and achieve mutual growth by expanding the market base."

Meanwhile, other investors in Precision Bio besides i-SENS include financial investors (FIs) such as Korea Investment Partners, Atinum Investment, DSC Investment, and Seoul Investment Partners.

This content was produced with the assistance of AI translation services.